FRANKFURT (Reuters) - Germany's Bayer AG has trumped rival bidders for Merck & Co Inc's consumer care business in a $14.2 billion deal, adding to a string of major cross-border deals in the healthcare ...

German pharmaceutical company Bayer has agreed to acquire Whitehouse Station, N.J.-based Merck & Co.’s OTC consumer care business for $14.2 billion. In 2013, 70 percent of Merck’s OTC consumer care ...

TRENTON, N.J. (AP) — Germany’s Bayer plans to buy Merck & Co.’s consumer health business, creating a combined medicine cabinet of household names from Bayer’s aspirin to Merck’s Claritin allergy pills ...

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its ...

Bayer announced today that it will acquire Merck's non-prescription and consumer care business for $14.2 billion, a move that will make Bayer the second biggest drug-maker in the world after Johnson & ...

In addition to Barclays, Bayer also received a Buy from UBS’s Geoff Haire in a report issued on March 26. However, on March 18, TipRanks – OpenAI reiterated a Hold rating on Bayer (LSE: 0P6S). The ...

In a flurry of decisions Friday, the European Medicines Agency’s human products committee recommended 17 new drugs for approval while letting Takeda withdraw from market an inflammatory bowel disease ...

This week, Bayer announced first-quarter 2025 results. Novo Nordisk and GSK plc announced licensing deals with smaller biotechs. The FDA granted approval to Merck's drug, Welireg, for its third ...